The goal of this clinical research study is to learn about gastrointestinal symptoms in participants who have undergone SC or RC and their impact on the quality of life of these participants.
To estimate the microbiota and bile acid profiles at multiple levels of the small intestine and proximal neo-colon in patients after RC and participants after SC.
Study Type
OBSERVATIONAL
Enrollment
20
Participants will be asked to swallow 2 small devices (called Capscan), which will collect samples of intestinal fluid as they move through participants small intestine and colon. This device is not FDA approved but has been deemed to have no significant risk. The investigator can explain how it is designed to work. Participants will also answer surveys about participants quality of life. Participants in this study will be over after all study procedures are completed.
MD Anderson Cancer Center
Houston, Texas, United States
Overall Survival (OS)
Time frame: Through study completion; an average of 1 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.